Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.

Izopet, J; Payen, J L; Alric, L; Sandres, K; Charlet, J P; Vinel, J P; Duffaut, M; Pascal, J P; Puel, J

Izopet, J; Payen, J L; Alric, L; Sandres, K; Charlet, J P; Vinel, J P; Duffaut, M; Pascal, J P; Puel, J.

Affiliation

Izopet J; Laboratoire de Virologie, CHU purpan, Toulouse, France. izopet@cict.fr

J Med Virol ; 54(2): 86-91, 1998 Feb.

Article in En | MEDLINE | ID: mdl-9496364

Subject(s)

Antiviral Agents/therapeutic use; Hepatitis C, Chronic/drug therapy; Interferon-alpha/therapeutic use; Adult; Aged; Alanine Transaminase/blood; Biomarkers/blood; Female; Hepacivirus/genetics; Hepatitis C, Chronic/blood; Hepatitis C, Chronic/diagnosis; Hepatitis C, Chronic/virology; Humans; Male; Middle Aged; Polymerase Chain Reaction/methods; Prospective Studies; RNA, Viral/blood; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Interferon-alpha / Hepatitis C, Chronic Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Med Virol Year: 1998 Document type: Article Affiliation country: France Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links